Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen

Nunn, Barbara; Chamberlain, Paul

doi:10.1111/j.2042-7158.1982.tb04796.x

Cited by 30 publications

(11 citation statements)

References 12 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the findings of Nunn et al in healthy volunteers6 using low doses of NSAIDs, the results of our study show a significant difference in platelet aggregation, when induced with collagen 1.0 μg/ml, after the use of naproxen compared to nabumetone. Al Balla et al ,7 studying the effect of nabumetone on platelet aggregation in healthy subjects, could not demonstrate significant differences in platelet aggregation induced by higher concentrations of collagen.…”

Section: Discussionsupporting

confidence: 93%

Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis

Knijff-Dutmer

Martens

Laar

1999

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

Objective-To test the hypothesis that nabumetone (a partially selective cyclooxygenase-(COX)-2 inhibitor) has less effect on platelet aggregation than naproxen (a non-selective COX-inhibitor) in patients with rheumatoid arthritis (RA). Methods-A crossover study in 10 RA patients was performed, using either nabumetone or naproxen for two weeks, and, after a washout period of two weeks, the other drug during another two weeks. Platelet aggregation studies were performed and bleeding time was assessed before and after each treatment period. Results-Maximum platelet aggregation induced by epinephrine and by collagen was significantly more reduced after the use of naproxen than of nabumetone; secondary aggregation induced by ADP and epinephrine disappeared more often by naproxen than by nabumetone. Bleeding times were not influenced. Conclusion-COX dependent platelet aggregation in RA patients seems to be more inhibited by naproxen than by nabumetone. This may be relevant for patients requiring non-steroidal anti-inflammatory drug treatment but who have an increased risk of bleeding as well.

show abstract

Section: Discussionsupporting

confidence: 93%

Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis

Knijff-Dutmer

Martens

Laar

1999

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

show abstract

“…Na bumetone shares many of the known side effects of NSAIDs; however, it has been sug gested that the drug has less gastrointestinal side effects than other NSAIDs [3]. Besides, the drug was also shown to have a weak anti platelet effect [4], In the present investigation we extend these earlier observations further by studying the ex vivo effects of nabumetone on the coagulation system, including platelet aggregation and bleeding time.…”

Section: Introductionsupporting

confidence: 69%

Interaction between Nabumetone – a New Non-Steroidal Anti-Inflammatory Drug – and the Haemostatic System ex vivo

Balla

Momen²,

Arfaj³

et al. 1990

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Twenty-six healthy volunteers were given the non-steroidal anti-inflammatory drug nabumetone (1 g/day p.o.) for 10 days. Platelet aggregation tests in response to adenosine diphosphate, adrenaline, collagen, arachidonic acid, and ristocetin and bleeding time and coagulation screening tests were performed on three occasions: (1) before drug therapy; (2) on the last day of drug therapy, and (3) 5 days after the end of therapy. No significant changes were noted in platelet aggregation, bleeding time, or the coagulation screening tests, except for a significant drop in fibrinogen during therapy and for 1 week after stopping the drug. The lack of any antiplatelet action and minimal effects on the coagulation parameters recommend the drug as a suitable antirheumatic in patients with bleeding disorders. The hypofibrinogenaemic action requires further studies.

show abstract

“…6-MNA competitively inhibits both cyclooxygenase isoenzymes, COX-1 and COX-2, by blocking arachidonate binding resulting in analgesic, antipyretic, and anti-inflammatory pharmacologic effects [5][6][7][8]. The enzymes COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin G 2 (PGG 2 ), the first step of the synthesis of prostaglandins and thromboxanes that are generated in rapid physiological responses [9,10]. Nabumetone is used in the treatment of osteoarthritis, rheumatoid arthritis and other musculoskeletal disorders.…”

Section: Nabumetonementioning

confidence: 99%

Analytical Procedure for Determination of Cyclooxygenase-2 Inhibitors in Biological Fluids by High Performance Liquid Chromatography: A Review

Carlucci

2009

AIAAMC

View full text Add to dashboard Cite

High-performance liquid chromatographic methods for the analysis of cyclooxygenase 2 inhibitors (COX-2) in biological fluids are reviewed. In particular, sample preparation and handling procedures, chromatographic conditions and detection methods are discussed. A summary of published high-performance liquid chromatographic assays for individual nabumetone, celecoxib, rofecoxib, nimesulide, etoricoxib, etodolac, deracoxib, lumiracoxib, valdecoxib, and meloxicam is included.

show abstract

Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen

Cited by 30 publications

References 12 publications

Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis

Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis

Interaction between Nabumetone – a New Non-Steroidal Anti-Inflammatory Drug – and the Haemostatic System ex vivo

Analytical Procedure for Determination of Cyclooxygenase-2 Inhibitors in Biological Fluids by High Performance Liquid Chromatography: A Review

Contact Info

Product

Resources

About